leisure time -WSS

leisure time

author：explore 2025-09-29 22:51:17 - browse：2927

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

entertainment

focus

WSS

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

Juul documents reveal insider tactics on political lobbying

STAT Boddities: What happens to the brain when we get scared?

Report cites 'urgent' need to recruit more diverse clinical trial participants

Doctors on social media are being harassed and cyberbullied

Why do we get seasonal allergies?

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medical leaders decry Supreme Court decision on affirmative action

GOP inquiry over gain

Continuity nursing helped my family in our darkest PICU moments

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Alkermes shareholders re

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Walensky prepares to leave CDC — and Congress — behind

Lilly’s obesity pill cuts 15% of weight at highest dose in mid

Hepatitis C has a cure — but many Americans still lack access to it

Why Eli Lilly’s earnings didn’t quite live up to the hype

explore

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Brazil's Jair Bolsonaro is barred from running for office until 2030

Study gives hint on South Asians’ higher risk of cardiovascular disease

GOP inquiry over gain

Juul documents reveal insider tactics on political lobbying

entertainment

focus

focus

focus